Navin Fluorine inaugurates Phase-1 of new cGMP-4 facility of Navin Molecular at Devas
The cGMP-4 facility will further strengthen the company's ability to serve global partners
The cGMP-4 facility will further strengthen the company's ability to serve global partners
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
The facility has been designed with a dual focus on efficiency and sustainability
Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
He has been associated with the Zydus Group since 2009
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
Subscribe To Our Newsletter & Stay Updated